Anna M Mohammadieh1,2, Kate Sutherland1,2, Logan B Kanagaratnam3,4, David W Whalley3,4, Mark J Gillett4,5, Peter A Cistulli1,2. 1. Department of Respiratory and Sleep Medicine, Royal North Shore Hospital, Sydney, Australia. 2. Charles Perkins Centre, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia. 3. Department of Cardiology, Royal North Shore Hospital, Sydney, Australia. 4. Faculty of Medicine and Health, The University of Sydney, Sydney, Australia. 5. Department of Emergency Medicine, Royal North Shore Hospital, Sydney, Australia.
Abstract
STUDY OBJECTIVES: Although obstructive sleep apnea (OSA) is a known risk factor for atrial fibrillation (AF), there is a paucity of data around its diagnosis and management in patients with AF. The objectives of this study were to compare the diagnostic accuracy of commonly used OSA screening tools in an AF population, including a level 3 portable sleep study device, and to examine the epidemiology of OSA in a hospital cohort with AF. METHODS: One hundred seven patients with AF recruited from 2 tertiary centers underwent a panel of OSA screening tools and in-laboratory polysomnography in randomized order. RESULTS: Oxygen desaturation index derived from a level 3 portable sleep study device performed best for moderate to severe and severe OSA, with excellent diagnostic accuracy (area under the curve, 0.899; 95% confidence interval, 0.838-0.960 and area under the curve, 0.925; 95% confidence interval, 0.859-0.991, respectively). Sixty-seven patients (62.6%) were newly diagnosed with OSA (31.8% mild, 18.7% moderate, 12.1% severe). CONCLUSIONS: Undiagnosed OSA is highly prevalent in a hospital AF cohort. However, it is characterized by a relative paucity of symptoms, markedly limiting the usefulness of history or screening questionnaires. This is the first study to find that a level 3 home sleep study device shows excellent diagnostic accuracy in patients with AF. This finding may inform AF management guidelines. CLINICAL TRIAL REGISTRATION: Registry: Australian New Zealand Clinical Trials Registry; Name: The validity and reliability of a portable device for the diagnosis of Obstructive Sleep Apnoea in patients with Atrial Fibrillation; URL:https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=371024; Identifier: ACTRN12616001016426.
STUDY OBJECTIVES: Although obstructive sleep apnea (OSA) is a known risk factor for atrial fibrillation (AF), there is a paucity of data around its diagnosis and management in patients with AF. The objectives of this study were to compare the diagnostic accuracy of commonly used OSA screening tools in an AF population, including a level 3 portable sleep study device, and to examine the epidemiology of OSA in a hospital cohort with AF. METHODS: One hundred seven patients with AF recruited from 2 tertiary centers underwent a panel of OSA screening tools and in-laboratory polysomnography in randomized order. RESULTS: Oxygen desaturation index derived from a level 3 portable sleep study device performed best for moderate to severe and severe OSA, with excellent diagnostic accuracy (area under the curve, 0.899; 95% confidence interval, 0.838-0.960 and area under the curve, 0.925; 95% confidence interval, 0.859-0.991, respectively). Sixty-seven patients (62.6%) were newly diagnosed with OSA (31.8% mild, 18.7% moderate, 12.1% severe). CONCLUSIONS: Undiagnosed OSA is highly prevalent in a hospital AF cohort. However, it is characterized by a relative paucity of symptoms, markedly limiting the usefulness of history or screening questionnaires. This is the first study to find that a level 3 home sleep study device shows excellent diagnostic accuracy in patients with AF. This finding may inform AF management guidelines. CLINICAL TRIAL REGISTRATION: Registry: Australian New Zealand Clinical Trials Registry; Name: The validity and reliability of a portable device for the diagnosis of Obstructive Sleep Apnoea in patients with Atrial Fibrillation; URL:https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=371024; Identifier: ACTRN12616001016426.
Authors: Craig T January; L Samuel Wann; Hugh Calkins; Lin Y Chen; Joaquin E Cigarroa; Joseph C Cleveland; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Karen L Furie; Paul A Heidenreich; Katherine T Murray; Julie B Shea; Cynthia M Tracy; Clyde W Yancy Journal: Heart Rhythm Date: 2019-01-28 Impact factor: 6.343
Authors: Waqas T Qureshi; Usama Bin Nasir; Shehabaldin Alqalyoobi; Wesley T O'Neal; Sagar Mawri; Salah Sabbagh; Elsayed Z Soliman; Mouaz H Al-Mallah Journal: Am J Cardiol Date: 2015-09-12 Impact factor: 2.778
Authors: Dominik Linz; Kadhim Kadhim; Anthony G Brooks; Adrian D Elliott; Jeroen M L Hendriks; Dennis H Lau; Rajiv Mahajan; Aashray K Gupta; Melissa E Middeldorp; Mathias Hohl; Chrishan J Nalliah; Jonathan M Kalman; R Doug McEvoy; Mathias Baumert; Prashanthan Sanders Journal: Int J Cardiol Date: 2018-07-25 Impact factor: 4.164
Authors: Dmitry M Yaranov; Athanasios Smyrlis; Natalia Usatii; Amber Butler; Joann R Petrini; Jose Mendez; Mark K Warshofsky Journal: Am J Cardiol Date: 2014-11-29 Impact factor: 2.778
Authors: Felipe N Albuquerque; Andrew D Calvin; Fatima H Sert Kuniyoshi; Tomas Konecny; Francisco Lopez-Jimenez; Gregg S Pressman; Thomas Kara; Paul Friedman; Naser Ammash; Virend K Somers; Sean M Caples Journal: Chest Date: 2011-09-08 Impact factor: 9.410
Authors: Apoor S Gami; Gregg Pressman; Sean M Caples; Ravi Kanagala; Joseph J Gard; Diane E Davison; Joseph F Malouf; Naser M Ammash; Paul A Friedman; Virend K Somers Journal: Circulation Date: 2004-07-12 Impact factor: 29.690
Authors: Anna Mary Mohammadieh; Hasthi U Dissanayake; Kate Sutherland; Seren Ucak; Philip De Chazal; Peter A Cistulli Journal: J Interv Card Electrophysiol Date: 2022-04-09 Impact factor: 1.900
Authors: Lindsay J Young; Steve Antwi-Boasiako; Joel Ferrall; Loren E Wold; Peter J Mohler; Mona El Refaey Journal: Life Sci Date: 2022-04-03 Impact factor: 6.780